GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies ...
Citi analyst Peter Verdult maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £19.00. The ...
GSK could still cause problems for the British firm: UBS. GlaxoSmithKline (GSK) saw its shares jump more than 6% after the ...
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a ...
The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.
2hon MSN
In fact, the company shares have seen a cumulative rise of 5.39 per cent or GBP 78.50. On Thursday, the green streak ...
London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...
Malay Mail on MSN6d
GSK’s Arexvy vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in MalaysiaGlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy has been approved in Malaysia for respiratory ...
The concerns surrounding Zantac also prompted UK health authorities to advise doctors in 2019 to cease prescribing specific formulations of the drug as a precautionary measure. Reports indicated that ...
Teva Pharmaceutical Industries Ltd. ADR-0.76% $19.75B ...
GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue ... As on 30-06-2024, the company has a total of 16.94 Crore shares outstanding.As of 8th Oct,2024, the GSK Pharma Share Price on NSE closed ...
GlaxoSmithKline (GSK) has accelerated the review of its Horlicks business in India, hoping to sell it for over $4 billion and potentially use the cash for Novartis' buy out deal. Bloomberg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback